U.S.
      SECURITIES AND EXCHANGE COMMISSION


Washington,
      D.C. 20549




FORM
      10-QSB


(Mark
      One)




x
      QUARTERLY REPORT UNDER
      SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934




For
      the
      quarterly period ended April 30, 2007




o
      TRANSITION REPORT UNDER
      SECTION 13 OR 15(D) OF THE EXCHANGE ACT




For
      the
      transition period from to




Commission
      File Number: 000-52836




Lifesciences
      Opportunities Incorporated


(Exact
      name of Small Business Issuer as specified in its Charter)




Florida
            20-0594204(State
                or other jurisdiction of
            (I.R.S.
                Employerincorporation
                or organization)
            Identification
                No.)




925
      S.
      Federal Highway, Suite 600, Boca Raton, Florida 33432


(Address
      of principal executive offices)




561-208-2929


(Issuer's
      telephone number)







(Former
      Name, former address and former fiscal year, if changed since last
      Report.)




Check
      mark whether the Issuer (1) has filed all reports required to be filed by
      Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the past
      12
      months (or for such shorter period that the registrant was required to file
      such
      reports), and (2) has been subject to such filing requirements for the past
      90
      days. Yes o No x




Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act). Yes x No o




APPLICABLE
      ONLY TO CORPORATE ISSUERS




State
      the
      number of shares outstanding of each of the issuer's classes of common equity,
      as of the latest practicable date: April 30, 2007, we had 45,000 shares of
      our
      Common Stock outstanding.




Transitional
      Small Business Disclosure Format (Check one): Yes oNo x







**INDEX**




**PART
                  I.   FINANCIAL INFORMATION**
              **1****Item
                  1.       Financial
                  Statements.**
              **1****Item
                  2.       Management's Discussion and
                  Analysis of Financial Condition and Plan of
                  Operations**
              **2****Item
                  3.       Controls and
                  Procedures**
              **4****PART
                  II.    OTHER INFORMATION**
              **5****Item
                  1.       Legal
                  Proceedings**
              **5****Item
                  2.       Unregistered Sales of Equity
                  Securities and Use of Proceeds**
              **5****Item
                  3.       Default Upon Senior
                  Securities**
              **5****Item
                  4.       Submission of Matters to a Vote of
                  Securities**
              **5****Item
                  5.       Other
                  Information**
              **5****Item
                  6.       Exhibits**
              **5****Signatures**
              **6**







**PART
      I. FINANCIAL INFORMATION**




**Item
      1.**  **Financial
      Statements.**




**LIFESCIENCES
      OPPORTUNITIES INCORPORATED**




CONDENSED
      FINANCIAL STATEMENTS


(Unaudited)




Table
      of
      Contents




Condensed
                Balance Sheet
            
            
            F-2Condensed
                Statements of Operations
            
            
            F-3Condensed
                Statements of Changes in Shareholders’ Deficit
            
            
            F-4Condensed
                Statements of Cash Flows
            
            
            F-5Notes
                to Condensed Financial Statements
            
            
            F-6







LIFESCIENCES
          OPPORTUNITIES INCORPORATED
 
 CONDENSED
          BALANCE SHEETS
 
 April
                    30,
                  2007
                
                January
                    31,
                  2007(Unaudited)
                
                (Audited)ASSETSCURRENT
                    ASSETSCash
                
                $
                6
                
                $
                6TOTAL
                    CURRENT ASSETS
                
                
                6
                
                
                6OTHER
                    ASSETSRestricted
                    cash
                
                
                30,237
                
                
                30,122TOTAL
                    ASSETS
                
                $
                30,243
                
                $
                30,128LIABILITIES
                    AND SHAREHOLDERS' DEFICITCURRENT
                    LIABILITIESAccounts
                    payable
                
                $
                2,894
                
                $
                3,894Accrued
                    expenses
                
                
                17,905
                
                
                15,225Loan
                    from shareholders
                
                
                10,100
                
                
                9,100TOTAL
                    CURRENT LIABILITIES
                
                
                30,899
                
                
                28,219TOTAL
                    LIABILITIES
                
                
                30,899
                
                
                28,219Commitments
                    and contingencies
                
                
                -
                
                
                -SHAREHOLDERS'
                    DEFICITCommon
                    stock, $0.0001 par value, 80,000,000 shares authorized,
                     40,000 shares issued and outstanding
                
                
                4
                
                
                4Additional
                    paid-in capital
                
                
                4,996
                
                
                4,996Stock
                    subscription received
                
                
                30,004
                
                
                30,004Accumulated
                    deficit
                
                
                (35,660
                )
                
                (33,095
                )TOTAL
                    SHAREHOLDERS' DEFICIT
                
                
                (656
                )
                
                1,909TOTAL
                    LIABILITIES AND SHAREHOLDERS' DEFICIT
                
                $
                30,243
                
                $
                30,128
 
 The
          accompanying notes are an integral part of these financial
          statements.
 
 F-2
  LIFESCIENCES
          OPPORTUNITIES INCORPORATED
 
 CONDENSED
          STATEMENTS OF OPERATIONS
 
 For
                    THREE months endedApril
                    30,
                  2007
                
                April
                    30,
                  2006(Unaudited)
                
                (Unaudited)REVENUES
                
                $
                -
                
                $
                -OPERATING
                    EXPENSES
                
                
                2,680
                
                
                2,567LOSS
                    FROM OPERATIONS
                
                
                (2,680
                )
                
                (2,567
                )OTHER
                    INCOME (EXPENSES)
                
                
                115
                
                
                -LOSS
                    BEFORE TAXES
                
                $
                (2,565
                )
                $
                (2,567
                )Weighted
                    average common shares outstanding - basic and
                    diluted
                
                
                40,000
                
                
                40,000NET
                    LOSS PER SHARE - basic and diluted
                
                $
                (0.06
                )
                $
                (0.06
                )
 
 The
          accompanying notes are an integral part of these financial
          statements.
 
 F-3
  LIFESCIENCES
          OPPORTUNITIES INCORPORATED
 
 CONDENSED
          STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT
 
 Common
                    Stock
                  80,000,000
                    shares authorizedShares
                  Issued
                
                Par
                    Value
                  $.0001
                    per share
                
                Additional
                  Paid-in
                  Capital
                
                Common
                  Stock
                  Subscriptions
                    Received
                
                Accumulated
                    Deficit
                
                TotalBALANCE
                    - JANUARY 31, 2006 (Audited)
                
                
                40,000
                
                $
                4
                
                $
                4,996
                
                $
                -
                
                $
                (9,460
                )
                $
                (4,460
                )Proceeds
                    from stock subscriptions
                
                
                
                
                
                -
                
                
                -
                
                
                30,004
                
                
                -
                
                
                30,004Net
                    Loss
                
                
                
                
                
                -
                
                
                -
                
                
                
                
                
                (23,635
                )
                
                (23,635
                )BALANCE
                    - JANUARY 31, 2007 (Audited)
                
                
                40,000
                
                $
                4
                
                $
                4,996
                
                $
                30,004
                
                $
                (33,095
                )
                $
                1,909Net
                    Loss
                
                
                
                
                
                -
                
                
                -
                
                
                -
                
                
                (2,565
                )
                
                (2,565
                )BALANCE
                    - APRIL 30, 2007 (Unaudited)
                
                
                40,000
                
                $
                4
                
                $
                4,996
                
                $
                30,004
                
                $
                (35,660
                )
                $
                (656
                )
 
 The
          accompanying notes are an integral part of these financial
          statements.
 
 F-4
  LIFESCIENCES
          OPPORTUNITIES INCORPORATED
 
 CONDENSED
          STATEMENTS OF CASH FLOWS
 
 For
                    the THREE months ended
                  April
                    30,2007
                
                2006(Unaudited)
                
                (Unaudited)Cash
                    flows from operating activitiesNet
                    loss
                
                $
                (2,565
                )
                $
                (2,567
                )Adjustments
                    to reconcile net loss to net cash used in operating
                    activities:Increase
                    in restricted cash
                
                
                (115
                )
                
                -Increase
                    in deferred financing cost
                
                
                -
                
                
                (6,645
                )Increase
                    (decrease) in accounts payable
                
                
                (1,000
                )
                
                6,645Increase
                    in accrued expenses
                
                
                2,680
                
                
                2,500Net
                    cash used by operating activities
                
                
                (1,000
                )
                
                (67
                )Cash
                    flows from financing activitiesProceeds
                    from shareholder loan
                
                
                1,000
                
                
                100Net
                    cash provided by financing activities
                
                
                1,000
                
                
                100NET
                    INCREASE (DECREASE) IN CASH
                
                
                -
                
                
                33CASH
                    AT BEGINNING OF PERIOD
                
                
                6
                
                
                40CASH
                    AT END OF PERIOD
                
                $
                6
                
                $
                73
  The
          accompanying notes are an integral part of these financial
          statements.
 
 F-5
  LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS
 
 NOTE
        1
– 
        ORGANIZATION AND GOING CONCERN
 
 Lifesciences
        Opportunities Incorporated (the “Company”) was incorporated under the laws of
        the State of Florida on January 12, 2004, to engage in any lawful corporate
        undertaking, including, but not limited to, selected mergers and acquisitions.
        The Company has had no operations to date other than issuing shares to its
        original shareholder.
 
 The
        Company has been formed to provide a method for a foreign or domestic private
        company to become a reporting ("public") company whose securities are qualified
        for trading in the United States secondary market.
 
 The
        Company will attempt to locate and negotiate with a business entity for the
        combination of that target company with us. The combination will normally
        take
        the form of a merger, stock-for-stock exchange or stock-for-assets exchange.
        No
        assurances can be given that we will be successful in locating or negotiating
        with any target company.
 
 These
        financial statements have been prepared assuming that the Company will continue
        as a going concern. The Company’s independent accountants have included a “going
        concern” paragraph in their audit report accompanying the financial statements
        for the year ended January 31, 2007 that cautions users of the statements
        that
        the Company needs to seek new sources or methods of financing or revenue
        to
        pursue its business strategy. The financial statements do no include any
        adjustments that might result from the outcome of this uncertainty. The Company
        anticipates that future revenue will be sufficient to cover certain operating
        expenditures, and, in the interim, will continue to pursue additional capital
        investment. However, there can be no assurance that the Company will be able
        to
        successfully acquire the necessary capital investment or revenue to continue
        their on-going efforts and continue operations. These factors, among others,
        create an uncertainty about the Company’s ability to continue as a going
        concern.
 
 Interim
        Financial Statements
 
 The
        interim financial statements presented herein are unaudited and have been
        prepared pursuant to the rules and regulations of the US Securities and Exchange
        Commission (SEC). Certain information and footnote disclosures normally included
        in financial statements prepared in accordance with accounting principles
        generally accepted in the United States of America have been condensed or
        omitted pursuant to such rules and regulations. The interim financial statements
        should be read in conjunction with the Company's audited financial statements,
        notes and accounting policies included in the Company's annual report on
        Form
        10KSB for the year ended January 31, 2007 as filed with the SEC. In the opinion
        of management, all adjustments (consisting only of normal recurring adjustments)
        which are necessary to provide for a fair presentation of financial position
        as
        of April 30, 2007 and the related operating results and cash flows for the
        interim period presented have been made. The results of operations, for the
        period presented are not necessarily indicative of the results to be expected
        for the year.
  F-6
 
 LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS
  NOTE
        2 –
 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
 Revenue
        Recognition
 
 The
        Company has adopted and follows the guidance provided in the Securities and
        Exchange Commission’s Staff Accounting Bulletin (“SAB”) No. 104, which provides
        guidance on the recognition, presentation and disclosure of revenue in financial
        statements.
 
 Use
        of
        Estimates
 
 The
        preparation of financial statements in conformity with generally accepted
        accounting principles requires management to make estimates and assumptions
        that
        affect the reported amounts of assets and liabilities, and disclosure of
        contingent assets and liabilities, at the date of these financial statements,
        and the reported amounts of revenues and expenses during the reporting period.
        Actual results could differ from those estimates.
 
 Cash
 
 The
        Company considers all highly liquid debt securities purchased with original
        or
        remaining maturities of three months or less to be cash equivalents. The
        carrying value of cash equivalents approximates fair value.
 
 Income
        Taxes
 
 Effective
        February 1, 2008, the Company adopted Financial Accounting Standards Board
        Interpretation (FIN) No: 48, “Accounting for Uncertainty in Income Taxes, an
        interpretation of Financial Accounting Standards Board (FASB) Statement on
        Financial Accounting Standards (SFAS) No. 109, Accounting for Income Taxes”. The
        interpretation addresses the determination of whether tax benefits claimed
        or
        expected to be claimed on a tax return should be recorded in the financial
        statements. Under FIN 48, the Company may recognize the tax benefit from
        an
        uncertain tax position only if it is more likely than not that the tax position
        will be sustained on examination by the taxing authorities, based on the
        technical merits of the position. The tax benefits recognized in the financial
        statements from such a position should be measured based on the largest benefit
        that has a greater than fifty percent likelihood of being realized upon ultimate
        settlement. FIN 48 also provides guidance on derecognition, classification,
        interest and penalties on income taxes, accounting in interim periods and
        requires increased disclosures. At the date of adoption, and as of April
        30,
        2007, the Company does not have a liability for unrecognized tax
        benefits.
 
 The
        Company files income tax returns in the U.S. federal jurisdiction and various
        states. The Company is subject to U.S. federal or state income tax examinations
        by tax authorities for the years after 2004. During the periods open to
        examination, the Company has Net Operating Losses (NOLs) and tax credit carry
        forwards for U.S. federal and state tax purposes that have attributes from
        closed periods. Since these NOLs and tax credit carry forwards may be utilized
        in future periods, they remain subject to examination.
  F-7
 
 LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS
 
 The
        Company’s policy is to record interest and penalties on uncertain tax provisions
        as income tax expense. As of April 30, 2007, the Company has no accrued interest
        or penalties related to uncertain tax positions.
 
 Loss
        Per Share
 
 The
        Company computes basic and diluted loss per share amounts pursuant to Statement
        of Financial Accounting Standards (SFAS) No. 128, “Earnings per Share.” There
        are no potentially dilutive shares outstanding and, accordingly, dilutive
        per
        share amounts are the same as basic per share amounts.
 
 Recent
        Accounting Pronouncements
  In
        February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for
        Financial Assets and Financial Liabilities —
        Including
        an amendment of FASB Statement No. 115" (FAS 159), which becomes effective
        for
        the Company on February 1, 2008, permits companies to choose to measure many
        financial instruments and certain other items at fair value and report
        unrealized gains and losses in earnings. Such accounting is optional and
        is
        generally to be applied instrument by instrument. The Company does not
        anticipate that the election, of this fair-value option, will have a material
        effect on its financial condition, results of operations, cash flows or
        disclosures.
  In
        September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" (SFAS
        157). SFAS 157 provides guidance for using fair value to measure assets and
        liabilities. SFAS 157 addresses the requests from investors for expanded
        disclosure about the extent to which companies measure assets and liabilities
        at
        fair value, the information used to measure fair value and the effect of
        fair
        value measurements on earnings. SFAS 157 applies whenever other standards
        require (or permit) assets or liabilities to be measured at fair value, and
        does
        not expand the use of fair value in any new circumstances. SFAS 157 is effective
        for financial statements issued for fiscal years beginning after November
        15,
        2007 and will be adopted by the Company in the first quarter of fiscal year
        2009. The Company is unable at this time to determine the effect that its
        adoption of SFAS 157 will have on its results of operations and financial
        condition.
  NOTE
        3 –
RESTRICTED CASH
 
 Restricted
        cash as of April 30, 2007 is comprised of $30,237 received from stock
        subscriptions and placed in an escrow account subject to the provisions of
        the
        initial public offering as described in Note 6.
  F-8
 
 LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS
 
 NOTE
        4 –
RELATED PARTY TRANSACTIONS
 
 The
        loans
        from shareholders as of April 30, 2007 and January 31, 2007 are $10,100 and
        $9,100, respectively. The notes are interest free and the Company imputed
        interest in accordance with the provisions of Accounting Principles Board
        Opinion (APBO) No. 21 Interest on Receivables and Payables. Accordingly,
        the
        interest expense for the periods ended April 30, 2007 and January 31, 2007
        are
        $180 and $510 respectively. The interest rate used for the periods was
        4.51%.
 
 NOTE
        5 –
ACCRUED EXPENSES
 
 Accrued
        expenses as of April 30, 2007 and January 31, 2007 are as follows
  April 30, 2007
              
              January 31, 2007Audit
                  fees
              
              $
              15,000
              
              $
              12,500Legal
                  fees
              
              
              2,215
              
              
              2,215Interest
                  expenses
              
              $
              690
              
              $
              510Total
                  accrued expenses
              
              $
              17,905
              
              $
              15,225
 
 NOTE
        6–
COMMON STOCK SUBSCRIBED
 
 In
        June,
        2006 the Company conducted a "blank check" offering subject to Rule 419 of
        Regulation C as promulgated by the U.S. Securities and Exchange Commission
        (SEC)
        under the Securities Act of 1933, as amended. The offering proceeds and the
        securities to be issued to investors must be deposited in an escrow account.
        While held in the escrow account, the deposited securities may not be traded
        or
        transferred. Except for an amount up to 10% of the deposited funds otherwise
        releasable under Rule 419, the deposited funds and the deposited securities
        may
        not be released until an acquisition meeting certain specified criteria has
        been
        consummated and a sufficient number of investors reconfirm their investment
        in
        accordance with the procedures set forth in Rule 419. Pursuant to these
        procedures, a new prospectus, which describes an acquisition candidate and
        its
        business and includes audited financial statements, will be delivered to
        all
        investors. The Company must return the pro rata portion of the deposited
        funds
        to any investor who does not elect to remain an investor. Unless a sufficient
        number of investors elect to remain investors, all investors will be entitled
        to
        the return of a pro rata portion of the deposited funds (plus interest, if
        any)
        and none of the deposited securities will be issued to investors. In the
        event
        an acquisition is not consummated within 18 months of the effective date
        of this
        prospectus, the deposited funds will be returned on a pro rata basis to all
        investors.
 
 The
        filing was declared to be effective by SEC on June 14, 2006. The Company
        offered
        10,000 shares through this offering of which 5,000 shares has been subscribed
        for as of April 30, 2007. The Company has placed the entire proceeds of $30,004
        from the sale of the shares in an Escrow Account and 90% of the proceeds
        are
        subject to release upon the earlier of (1) written notification by the Company
        of the need for all, or substantially all, of such net proceeds for the purpose
        of facilitating a business combination; or (2) 18 months after the effective
        date of this registration statement.
  F-9
 
 LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS
 
 No
        funds
        will be disbursed from the escrow account for the payment of salaries or
        reimbursement of expenses incurred by our officers and directors. In no event
        will the escrowed funds be used for any purpose other than implementation
        of a
        business combination.
 
 NOTE
        7 –
SUBSEQUENT EVENTS
 
 During
        September 2007, the Company entered into an agreement and plan of merger
        ("Merger Agreement") with Dr. TATTOFF, LLC, a California limited liability
        company, ("TATTOFF"), whereby TATTOFF will be merged into the Company. Under
        the
        terms of the Merger Agreement, the Company will issue up to 8,400,000 shares
        of
        its restricted common stock and common stock purchase warrants to purchase
        up to
        an aggregate of 1,005,000 shares of the Company's common stock, exercisable
        at
        $1.25 per share subject to adjustment. The common stock and warrants shall
        be
        issued on a post-forward split basis as described below. In addition to
        complying with Rule 419 requirements, the closing of the merger is conditioned
        upon the Company's shareholders approving proposals to amend the Company's
        articles of incorporation to change its corporate name to Dr. TATTOFF, Inc.
        and
        to amend the Company's articles of incorporation to effectuate a 1 to 55.5
        forward split of the Company's outstanding common stock. The completion of
        the
        merger will be subject to satisfaction of additional conditions described
        under
        the Merger Agreement.
  F-10




**Item
                2.**
            **Management's
                Discussion and Analysis of Financial Condition and Plan of
                Operations**




**General**




Forward-Looking
      Statements




The
      following discussion of the financial condition and results of operations should
      be read in conjunction with our financial statements and related notes thereto.
      The following discussion contains forward-looking statements. Lifesciences
      Opportunities Incorporated is referred to herein as "the Company", "we" or
      "our.” The words or phrases "would be," "will allow," "intends to," "will likely
      result," "are expected to," "will continue," "is anticipated," "estimate,"
      "project," or similar expressions are intended to identify "forward-looking
      statements". Such statements include those concerning our expected financial
      performance, our corporate strategy and operational plans. Actual results could
      differ materially from those projected in the forward-looking statements as
      a
      result of a number of risks and uncertainties. Statements made herein are as
      of
      the date of the filing of this Form 10-QSB with the Securities and Exchange
      Commission and should not be relied upon as of any subsequent date. Unless
      otherwise required by applicable law, we do not undertake, and we specifically
      disclaim any obligation, to update any forward-looking statements to reflect
      occurrences, developments, unanticipated events or circumstances after the
      date
      of such statement.




**Plan
      of Operations**




The
      Company intends to seek to acquire assets or shares of an entity actively
      engaged in a business that generates revenues, in exchange for its securities.
      During December 2006, the Company closed its 419 offering and collected gross
      proceeds of $30,000. The balance of funds held with an escrow agent totaled
      $30,000. Under the 419 Rule, the shareholders are entitled to have monies
      returned to them if they do not reconfirm the 419 merger candidate or eighteen
      months pass without finding a merger candidate; therefore these funds may or
      may
      not be released to the Company. Our sole officer and director has begun seeking
      an acquisition or merger between the Company and such other company. As of
      the
      date of this report, the Company did not identify a merger
      candidate.




Due
      to
      the Company's intent to remain a shell corporation until a merger or acquisition
      candidate is identified, it is anticipated that its cash requirements shall
      be
      minimal, and that all necessary capital, to the extent required, will be
      provided by the Company's sole officer/director. The Company also does not
      expect to acquire any plant or significant equipment.




Our
      initial offering was a "blank check" offering due to the fact that we are a
      development stage company that has no specific business plan or purpose and
      we
      indicated that our business plan or purpose was to merge with or be acquired
      by
      an unidentified company.




Once
      a
      merger candidate is identified we are required to file a post-effective
      amendment to our registration statement on Form SB-2 (File No-333-117100)
      detailing the proposed combination and requesting a reconfirmation from
      stockholders that purchased shares in its public offering to reconfirm their
      election to invest in the Company's shares. The post-effective amendment is
      required to contain information about our proposed merger candidate and its
      business, including audited financial statements and the proposed use of the
      funds to be disbursed from the escrow account.




2




Our
      reconfirmation offering is subject to Rule 419 under the Securities Act, and
      the
      post-effective amendment will also include the terms of the reconfirmation
      offer
      mandated by Rule 419. Among other things, the fair market value of the business
      or assets must represent at least 80% of the maximum proceeds of our prior
      offering. For purposes of this blank check offering, the fair market value
      of
      the business or assets to be acquired must be at least $48,000.




The
      offering proceeds and shares held in escrow may be released to us and the
      investors, respectively, after the escrow agent has received a signed
      representation from us and any other evidence acceptable by the escrow agent
      that:




(1)  We
      have
      executed a Merger Agreement and that the fair value of the business represents
      at least $48,000, and we have filed the required post-effective
      amendment;




(2)  The
      post-effective amendment has been declared effective, the mandated
      reconfirmation offer prescribed by Rule 419 has been completed and we have
      satisfied all of the prescribed conditions of the reconfirmation
      offer.




The
      Company has no full time employees. Our sole officer has agreed to allocate
      a
      portion of his time to the activities of the Company, without compensation.
      This
      officer anticipates that the business plan of the Company can be implemented
      by
      devoting approximately 10 hours each per month to the business affairs of the
      Company and, consequently, conflicts of interest may arise with respect to
      the
      limited time commitment by such officer. The Company does not expect any changes
      in the number of employees.




We
      currently rely on advances from our affiliates for working capital. Our
      affiliates have advanced our company working capital up to cover expenses.
      Advances are non-interest bearing and repayable on or before 24 months from
      the
      date of the advance. Repayment of advances will not be a condition completing
      an
      acquisition.




**Subsequent
      Events**




As
      reported on Form 8-K Current Report filed on September 28, 2007, the Company
      entered into an agreement and plan of merger ("Merger Agreement") with Dr.
      TATTOFF, LLC, a California limited liability company ("TATTOFF") dated September
      7, 2007, whereby TATTOFF will be merged into the Company. Under the terms of
      the
      Merger Agreement, the Company will issue up to 8,400,000 shares of its
      restricted common stock and common stock purchase warrants to purchase up to
      an
      aggregate of 1,005,000 shares of the Company's common stock, exercisable at
      $1.25 per share subject to adjustment. The common stock and warrants shall
      be
      issued on a post-forward split basis as described below. In addition to
      complying with Rule 419 requirements, the closing of the merger is conditioned
      upon the Company's shareholders approving proposals to amend the Company's
      articles of incorporation to change its corporate name to Dr. TATTOFF, Inc.
      and
      to amend the Company's articles of incorporation to effectuate a 1 to 55.5
      forward split of the Company's outstanding common stock. The completion of
      the
      merger will be subject to satisfaction of additional conditions described under
      the Merger Agreement.




Dr.
      TATTOFF, LLC was organized under the laws of the state of California in 2004.
      TATTOFF is a provider of marketing and practice management services to
      physicians who perform tattoo removal, hair removal services (regardless of
      method) and laser-based skin care services. TATTOFF endeavors to develop laser
      center sites and to provide turnkey marketing services, human resources and
      staffing services, patient management services, technical solutions, office
      management and other non-medical services to the physicians and medical staff
      at
      each of its laser centers. TATTOFF owns the registered trademark, Dr. TATTOFF,
      and licenses the use of the trademark as part of the management services
      provided to physicians. These services are provided directly to the physicians
      or to their medical corporations, medical groups or other affiliated entities.
      TATTOFF currently has three laser centers in Southern California: Beverly Hills,
      Irvine and Encino. For the fiscal year ended December 31, 2006 TATTOFF had
      revenues of approximately $947,000 and a net loss of approximately $(693,000).
      TATTOFF's principal executive offices are located at 8447 Wilshire Boulevard,
      Suite 102, Beverly Hills, CA 90211.




3




**Item
              3.**
            **Controls
                and Procedures**




Evaluation
      of disclosure controls and procedures




As
      of the
      end of the period covered by this report, we carried out an evaluation of the
      effectiveness of the design and operation of our disclosure controls and
      procedures pursuant to Exchange Act Rule 13a-15(e). This evaluation was done
      under the supervision and with the participation of our Principal Executive
      Officer and Principal Financial Officer. Based upon that evaluation, our
      Principal Executive Officer and Principal Financial Officer concluded that
      the
      design and operation of our disclosure controls and procedures are not effective
      due to the Company’s failure to timely file its quarterly reports and annual
      with the SEC. This weakness is due to the Company’s lack of staffing, as the
      Company is a "blank check" company with one officer/employee that devotes
      limited time to the Company's business. We believe that the weakness will be
      resolved once the Company completes its reorganization.




Changes
      in internal controls




There
      were no changes in our internal controls or in other factors during the period
      covered by this report that have materially affected, or is likely to materially
      affect the Company’s internal controls over financial reporting.




4


**PART
      II. OTHER INFORMATION**




**Item
              1.**
            **Legal
                Proceedings**




None.




**Item
              2.**
            **Unregistered
                Sales of Equity Securities and Use of
                Proceeds**




None.




**Item
              3.**
            **Default
                Upon Senior Securities**




None.




**Item
              4.**
            **Submission
                of Matters to a Vote of
                Securities**




None.




**Item
              5.**
            **Other
                Information**




None.




**Item
              6.**
            **Exhibits**




Exhibits
      required by Item 601 of Regulation S-B




31.1
            Form
              302 Certification of Chief Executive Officer31.2
            Form
              302 Certification of Principal Financial Officer32.1
            Form
              906 Certification of Chief Executive Officer and Principal Financial
              Officer




5


Signatures




Pursuant
      to the requirements of the Securities Exchange Act of 1934, the Registrant
      has
      duly caused this report to be signed on its behalf by the undersigned as a
      duly
      authorized officer of the Registrant.




Lifesciences
      Opportunities Incorporated





By:
            /s/
                Roland PerryRoland
                PerryChief
                Executive Officer andPrincipal
                Financial Officer





DATED:
      October 4, 2007




6